Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033246 | 0.77 | HTR1B (0.42) | KMT2A | |
| SCHEMBL16661732 | 0.75 | — | — | |
| Fluoride SCHEMBL27524402 | 0.75 | HTR1B (0.41) | KMT2A | |
| SCHEMBL22100463 | 0.74 | LMNA (0.54) | CHRNB2CHRNA4LMNATDP1CYP3A4 | |
| SCHEMBL4671885 | 0.74 | MAPK1 (0.49) | CHRNB2CHRNA4LMNATDP1CYP2D6 | |
| SCHEMBL7104126 | 0.73 | CHRNB2 (0.67) | CHRNB2CHRNA4LMNACYP3A4CYP2D6 | |
| SCHEMBL18812368 | 0.73 | CYP19A1 (0.67) | LMNACYP3A4CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL30338591 | 0.72 | CHRNB2 (0.68) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL171896 | 0.72 | CHRNB2 (0.68) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL434891 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, HNMT, CHRM3 | CHRNB2 32/4885CHRNA4 34/4885LMNA 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.